Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Inflammatory Bowel Disease
•
Gastroenterology
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What is your approach to managing ILD associated with inflammatory bowel disease?
Related Questions
How would you manage a patient with Crohn's disease on a biologic and presents with non-bloody diarrhea, normal-appearing mucosa on sigmoidoscopy but severe colitis on biopsy with a positive CMV stain?
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
